{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:10:19Z","timestamp":1768594219444,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107802","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T07:35:05Z","timestamp":1725521705000},"page":"107802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["FL118: A potential bladder cancer therapeutic compound targeting H2A.X identified through library screening"],"prefix":"10.1016","volume":"153","author":[{"given":"Guangrui","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongfei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luhua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engaung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaohu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-591X","authenticated-orcid":false,"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2024.107802_b0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107802_b0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107802_b0015","first-page":"2350","article-title":"Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107802_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.tetlet.2024.154912","article-title":"An alternative synthesis for Exatecan mesylate","volume":"136","author":"Lu","year":"2024","journal-title":"Tetrahedron Lett."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107802_b0025","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cmdc.202000753","article-title":"Synthesis and biological evaluation of 10-substituted camptothecin derivatives with improved water solubility and activity","volume":"16","author":"Yang","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2024.107802_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111971","article-title":"Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin","volume":"187","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107802_b0035","unstructured":"Xu Xiaoshan, Research on the Design, Synthesis, and Antitumor Activity of New Quinolone-Type Top I Inhibitors, 2018."},{"key":"10.1016\/j.bioorg.2024.107802_b0040","unstructured":"Chen Haile, Research on the Design, Synthesis, and Structure-Activity Relationships of Camptothecin-Based Antitumor Drugs, 2017."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107802_b0045","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.bmcl.2017.02.066","article-title":"Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives","volume":"27","author":"Zhu","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"20","key":"10.1016\/j.bioorg.2024.107802_b0050","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/j.bmcl.2017.09.012","article-title":"Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives","volume":"27","author":"Yang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bioorg.2024.107802_b0055","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.bmcl.2014.06.060","article-title":"Design and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents","volume":"24","author":"Zhao","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107802_b0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/mp4004282","article-title":"Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration","volume":"11","author":"Zhao","year":"2014","journal-title":"Mol. Pharm."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107802_b0065","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.bmcl.2005.05.108","article-title":"Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers","volume":"15","author":"Gao","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107802_b0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0960-894X(00)00005-6","article-title":"Novel C-ring analogues of 20(S)-camptothecin. Part 3: synthesis and their in vitro cytotoxicity of A-, B- and C-ring analogues","volume":"10","author":"Subrahmanyam","year":"2000","journal-title":"Bioor. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107802_b0075","unstructured":"Liu Yingqian, Yang Chengjie, Raymond Cobbler-Lau, Li Junzai, Zhang Xiaoshuai, Xu Xiaoshan, Yang Guanzhou, Chen Cheng, Zhang Junxiang, A 7-Ethyl-10-Fluoro-Camptothecin-20-Cinnamate Compound, Preparation Method, and Uses, p. 16."},{"key":"10.1016\/j.bioorg.2024.107802_b0080","unstructured":"Liu Yingqian, Wang Jingru, Yang Chengjie, Xu Chuanrui, Zhang Mi, Bai Yinpeng, Li Haixin, Hu Yongmei, Ma Yue, He Yinghui, Luo Xiongfeng, Preparation of a camptothecin boronic acid compound and its antitumor uses, p. 6."},{"key":"10.1016\/j.bioorg.2024.107802_b0085","unstructured":"Liu Yingqian, Chen Haile, Yang Chengjie, Raymond Cobbler-Lau, Li Hu, Gao Jianmei, A 9-Piperazine sulfonamide-10-hydroxycamptothecin compound and its preparation method and antitumor uses, p. 12."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107802_b0090","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protocols"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107802_b0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107802_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073693","article-title":"FL118 is a potent therapeutic agent against chronic myeloid leukemia resistant to BCR-ABL inhibitors through targeting RNA helicase DDX5","volume":"25","author":"Takeda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107802_b0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13046-023-02787-x","article-title":"Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence","volume":"42","author":"Li","year":"2023","journal-title":"J. Experiment. Clin. Cancer Res.: CR"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107802_b0110","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1002\/ctm2.881","article-title":"FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy","volume":"12","author":"Ling","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bioorg.2024.107802_b0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","article-title":"FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance","volume":"14","author":"Westover","year":"2015","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107802_b0120","first-page":"370","article-title":"Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Cancer Res."},{"issue":"5\u20136","key":"10.1016\/j.bioorg.2024.107802_b0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107802_b0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107802_b0135","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824007077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824007077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:21:49Z","timestamp":1738203709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824007077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"alternative-id":["S0045206824007077"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107802","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FL118: A potential bladder cancer therapeutic compound targeting H2A.X identified through library screening","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107802"}}